|
NPPA fixes retail price of 36 formulations
|
|
Our Bureau, New Delhi
September 21 , 2022
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 36 formulations including several anti-diabetes drugs under the Drugs (Prices Control) Order, 2013, based on the decision of an Authority meeting held this month.
The formulations, for which the prices were fixed include type 2 diabetes medications such as dapagliflozin and metformin hydrochloride extended release tablets marketed by Hetero Healthcare; sitagliptin phosphate and metformin hydrochloride tablets marketed by Aprica Healthcare Ltd and Psychotropics India Ltd; sitagliptin and metformin hydrochloride tablets from Hetero Healthcare Ltd, various strengths of sitagliptin and metformin hydrochloride (sustained release) tablets from Aprica Healthcare and Aristo Pharmaceuticals, extended release tablets of the same combination marketed by German Remedies Pharmaceuticals, among others.
The other formulations for which the NPPA has fixed the retail prices include a combination of sodium alginate, sodium bicarbonate and calcium carbonate oral suspension from Cadila Pharmaceuticals; cilnidipine and metoprolol succinate extended release tablets marketed by Troikaa Pharmaceuticals; paracetamol infusion IP (1% w/v) from Mankind Prime Labs Pvt Ltd; telmisartan and metoprolol succinate extended release tablets from Indchemie Health Specialities Pvt Ltd; telmisartan, amlodipine and hydrochlorothiazide tablets, marketed by Cipla Ltd; etoricoxib and paracetamol tablets marketed by Wockhardt Ltd, amoxycillin & potassium clavulanate oral suspension IP and Aspirin gastro-resistant and atorvastatin capsules marketed by Mankind Pharma Ltd among others.
The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified in the Order issued by the NPPA and the manufacturer may add Goods and Services Tax (GST) only if they have paid actually or it is payable to the government on the retail price mentioned in the Order.
Besides, in another Order, the NPPA has fixed the retail price of the combination of rosuvastatin and clopidogrel capsule, manufactured by Sun Pharma, after the product was launched by the company without obtaining prior price approval.
The price of each hard gelatine capsules containing rosuvastatin 10 mg, clopidogrel 75 mg at Rs. 13.02.
The Authority, in its 101st meeting held on September 7, 2022, said that it “deliberated upon the matter in detail regarding the need for price fixation of each hard gelatin capsules containing rosuvastatin 10mg+ clopidogrel 75 mg due to launch of the same by Sun Pharmaceutical Industries Ltd without obtaining prior price approval.”
Accordingly, the Authority approved the retail price of the formulation at Rs. 13.02 per capsules excluding GST, it said.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|